Quotient Sciences has made a $15m investment into creating this new site, in an aim to expand its manufacturing operations in the US.
The new 45,000-square-foot facility, which will be a center of excellence for early-phase formulation development and clinical trial manufacturing, will be located near Philadelphia, PA.
The site will focus on the development of small molecule oral drugs, and support development programs from preclinical to clinical proof-of-concept. It also will allow for scale-up to late-phase manufacturing. Commercial product supply will continue at Quotient’s other Pennsylvania facility while the new facility is being built.
According to a statement made by Mark Egerton, CEO of Quotient, the new facility is designed to optimize the company’s ability to work with highly potent and poorly soluble molecules, which are currently a large part of the industry’s pipeline.
Quotient’s capacity to provide its Translational Pharmaceutics program to US customers will also be expanded by this new facility. The platform integrates formulation development, manufacturing, and clinical research.
The new facility is designed to handle both potent and non-potent products with six high-potency good manufacturing practice (GMP) suites.
The company plans to expand even more and will announce further expansion in the coming months.
Last year at the 2017 Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists (AAPS), Quotient announced its rebranding from Quotient Clinical to Quotient Sciences. The company has 700 employees, five operating sites across the US and the UK.
Quotient was unable to provide further comment at this time.